Altre lingue Bristol-Myers Squibb Company Börse Stuttgart

Azioni

BRM

US1101221083

Mercato chiuso - Börse Stuttgart Altri mercati azionari 20:34:47 12/07/2024			Variaz. 5gg	Var. 1 gen.
37,39 ^EUR	-0,33%		+2,62%	-19,68%

02/07	Cartesian Therapeutics, Inc. nomina Kemal Malik nel suo Consiglio di Amministrazione	CI
01/07	Bristol-Myers Squibb pagherà 2,7 milioni di dollari per risolvere un potenziale caso di anticoncorrenza, secondo l'agenzia israeliana	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day	08/07
Cartesian Therapeutics, Inc. Appoints Kemal Malik to its Board of Directors	02/07
Bristol-Myers Squibb to Pay $2.7 Million to Settle Potential Anti-Competition Case, Israeli Agency Says	01/07
Bristol Myers Squibb Named to Dow Jones Sustainability Index North America	01/07
Eisai Co., Ltd. Agrees to End Its Global Strategic Collaboration with Bristol Myers Squibb for the Co-Development and Co-Commercialization of farletuzumab ecteribulin	01/07
Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	27/06
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	26/06
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	26/06
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06
European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab	24/06
Bristol Myers : approbation accélérée en cancer colorectal	24/06
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)	22/06
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	22/06
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval	21/06
US FDA approves Bristol Myers' colorectal cancer therapy	21/06
Bristol-Myers Squibb Says EMA Validates Application for Subcutaneous Opdivo	21/06
Bristol Myers : demande validée pour Opdivo sous-cutané	21/06
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab	21/06

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

In prima pagina

Il CEO di Bristol-Myers dice che l'azienda è in fase di transizione

09 gennaio 2024 alle 19:06